1. Home
  2. REAX vs GYRE Comparison

REAX vs GYRE Comparison

Compare REAX & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • REAX
  • GYRE
  • Stock Information
  • Founded
  • REAX 2018
  • GYRE 2002
  • Country
  • REAX United States
  • GYRE United States
  • Employees
  • REAX N/A
  • GYRE N/A
  • Industry
  • REAX
  • GYRE Biotechnology: Pharmaceutical Preparations
  • Sector
  • REAX
  • GYRE Health Care
  • Exchange
  • REAX Nasdaq
  • GYRE Nasdaq
  • Market Cap
  • REAX 872.2M
  • GYRE 897.1M
  • IPO Year
  • REAX N/A
  • GYRE N/A
  • Fundamental
  • Price
  • REAX $3.95
  • GYRE $8.07
  • Analyst Decision
  • REAX Strong Buy
  • GYRE
  • Analyst Count
  • REAX 2
  • GYRE 0
  • Target Price
  • REAX $6.00
  • GYRE N/A
  • AVG Volume (30 Days)
  • REAX 918.5K
  • GYRE 412.5K
  • Earning Date
  • REAX 08-06-2025
  • GYRE 08-12-2025
  • Dividend Yield
  • REAX N/A
  • GYRE N/A
  • EPS Growth
  • REAX N/A
  • GYRE N/A
  • EPS
  • REAX N/A
  • GYRE 0.02
  • Revenue
  • REAX $1,417,877,000.00
  • GYRE $100,643,000.00
  • Revenue This Year
  • REAX $43.20
  • GYRE $21.04
  • Revenue Next Year
  • REAX $15.30
  • GYRE $89.64
  • P/E Ratio
  • REAX N/A
  • GYRE $100.77
  • Revenue Growth
  • REAX 81.30
  • GYRE N/A
  • 52 Week Low
  • REAX $3.55
  • GYRE $6.11
  • 52 Week High
  • REAX $6.75
  • GYRE $19.00
  • Technical
  • Relative Strength Index (RSI)
  • REAX 36.85
  • GYRE 43.87
  • Support Level
  • REAX $3.86
  • GYRE $7.99
  • Resistance Level
  • REAX $4.06
  • GYRE $8.55
  • Average True Range (ATR)
  • REAX 0.17
  • GYRE 0.64
  • MACD
  • REAX -0.02
  • GYRE -0.05
  • Stochastic Oscillator
  • REAX 24.41
  • GYRE 28.82

About REAX The Real Brokerage Inc.

The Real Brokerage Inc is a technology-powered real estate brokerage firm located in the United States and Canada. It has developed a proprietary transaction management and brokerage operations software called reZEN, which powers nearly all of its brokerage operations, enabling efficiency, automation, and flexibility by incorporating end-to-end transaction management, automated compliance and brokerage oversight, integrated payments and financial services, Leo CoPilot, and open API for customization. In addition, the company also offers mortgage brokering and title services. The company's operating segments are North American Brokerage, which derives key revenue, One Real Title, One Real Mortgage, and Real Wallet. Geographically, it derives key revenue from the United States.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage pharmaceutical company developing and commercializing small-molecule anti-inflammatory and anti-fibrotic drugs targeting organ diseases, focusing specifically on organ fibrosis. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: